Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;14(23):5936.
doi: 10.3390/cancers14235936.

Trop-2 as a Therapeutic Target in Breast Cancer

Elizabeth Sakach  1 , Ruth Sacks  1 , Kevin Kalinsky  1
Affiliations
Review

Trop-2 as a Therapeutic Target in Breast Cancer

Elizabeth Sakach et al. Cancers (Basel). .

Abstract

The emergence of Trop-2 as a therapeutic target has given rise to new treatment paradigms for the treatment of patients with advanced and metastatic breast cancer. Trop-2 is most highly expressed in triple negative breast cancer (TNBC), but the receptor is found across all breast cancer subtypes. With sacituzumab govitecan, the first FDA-approved, Trop-2 inhibitor, providing a survival benefit in patients with both metastatic TNBC and hormone receptor positive breast cancer, additional Trop-2 directed therapies are under investigation. Ongoing studies of combination regimens with immunotherapy, PARP inhibitors, and other targeted agents aim to further harness the effect of Trop-2 inhibition. Current investigations are also underway in the neoadjuvant and adjuvant setting to evaluate the therapeutic benefit of Trop-2 inhibition in patients with early stage disease. This review highlights the significant impact the discovery Trop-2 has had on our patients with heavily pretreated breast cancer, for whom few treatment options exist, and the future direction of novel Trop-2 targeted therapies.

Keywords: Trop-2; antibody drug conjugate; breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cubas R., Li M., Chen C., Yao Q. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim. et Biophys. Acta. 2009;1796:309–314. doi: 10.1016/j.bbcan.2009.08.001. - DOI - PubMed
    1. Goldenberg D.M., Stein R., Sharkey R.M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–29006. doi: 10.18632/oncotarget.25615. - DOI - PMC - PubMed
    1. Zaman S., Jadid H., Denson A.C., Gray J.E. Targeting Trop-2 in solid tumors: Future prospects. OncoTargets Ther. 2019;12:1781–1790. doi: 10.2147/OTT.S162447. - DOI - PMC - PubMed
    1. Fang Y.J., Lu Z.H., Wang G.Q., Pan Z.Z., Zhou Z.W., Yun J.P., Zhang M.F., Wan D.S. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int. J. Color. Dis. 2009;24:875–884. doi: 10.1007/s00384-009-0725-z. - DOI - PubMed
    1. Fong D., Moser P., Krammel C., Gostner J., Margreiter R., Mitterer M., Gastl G., Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br. J. Cancer. 2008;99:1290–1295. doi: 10.1038/sj.bjc.6604677. - DOI - PMC - PubMed